Dth

Synonyms: DFHBI-thalidomide
Dth(DFHBI-thalidomide)是一种基于 RNA 适体的 PROTAC 降解剂,通过将 RNA 支架上的 3′ 模块替换为目标蛋白对应的 RNA 适体即可降解多种内源性蛋白质(如 mCherry、p50、p65 和 E2F1),并可上调 IκB-α 和 Bax、下调 Bcl-2 和 VEGF,同时在与 Broccoli RNA 适配体结合后产生绿色荧光以实现 RNA 支架的示踪,可用于癌症相关研究(粉色:Ligands for Target Protein for PROTAC 配体 (MS-Z03544);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-L41837))。
Dth
产品编号: MS-S79936 分子式: C30H29F2N5O6 分子量: 593.58
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Dth(DFHBI-thalidomide)是一种基于 RNA 适体的 PROTAC 降解剂,通过将 RNA 支架上的 3′ 模块替换为目标蛋白对应的 RNA 适体即可降解多种内源性蛋白质(如 mCherry、p50、p65 和 E2F1),并可上调 IκB-α 和 Bax、下调 Bcl-2 和 VEGF,同时在与 Broccoli RNA 适配体结合后产生绿色荧光以实现 RNA 支架的示踪,可用于癌症相关研究(粉色:Ligands for Target Protein for PROTAC 配体 (MS-Z03544);蓝色:Cereblon 配体 (MS-V29738);黑色:连接子 (MS-L41837))。

生物实验数据

生物活性 Dth (DFHBI-thalidomide) is an RNA aptamer-based PROTAC degrader that degrades multiple endogenous proteins (such as mCherry, p50, p65, and E2F1) by replacing the 3′ module on the RNA scaffold with an RNA aptamer corresponding to the target protein, upregulates IκB-α and Bax while downregulating Bcl-2 and VEGF, and upon binding to the Broccoli RNA aptamer produces green fluorescence to enable tracing of the RNA scaffold, making it useful for cancer-related research (pink: Ligands for Target Protein for PROTAC ligand (MS-Z03544); blue: Cereblon ligand (MS-V29738); black: linker (MS-L41837)).
IC50 & Target

p50

 

p65

 

体外研究
(In Vitro)

Dth (20 μM; 1.5 h) 可通过 Broccoli-MS2 RNA 支架在 HEK-293T 细胞中与外源性 mCherry 共定位。
Dth (20 μM; 24 h) 可通过 Broccoli-MS2 RNA 支架在 CHO 细胞中诱导外源性 mCherry 的靶向降解。
Dth (10-160 μM; 24 h) 可在 MCF-7 细胞中通过 Broccoli-p50 RNA 支架诱导内源性 p50 的靶向降解。
Dth (20 μM; 24 h) 可诱导表达 B-20A-p50 RNA 支架的 MCF-7 细胞中内源性 p50 降解,进而抑制 NF-κB 活性并改变下游通路蛋白的表达。
Dth (10-30 μM; 24 h) 可在 MCF-7 细胞中通过各自基于 Broccoli 的 RNA 支架诱导内源性 p65 和 E2F1 的靶向降解。
Dth (10-30 μM; 24-48 h) 可通过三适配体 p50-20A-E2F1 RNA 支架在 MCF-7 细胞中同时诱导内源性 p50 和 E2F1 的靶向降解,其对细胞增殖的抑制作用强于单靶点降解。

Western Blot Analysis

Cell Line: Chinese hamster ovary CHO cells (stably expressing MCP-mCherry and transfected with plasmids encoding Broccoli-MS2 RNA scaffolds with varying polyA linkers)
Concentration: 20 μM
Incubation Time: 24 h
Result: Showed all RNA scaffold linker lengths induced partial mCherry degradation, with 10 polyA (10A) and 30 polyA (30A) linkers yielding better results.
Confirmed reduced red fluorescence signals corresponding to mCherry degradation via fluorescence microscopy.
Revealed thalidomide and DFHBI alone did not induce significant mCherry degradation.

Western Blot Analysis

Cell Line: human breast cancer MCF-7 cells (transfected with plasmids encoding Broccoli-p50 RNA scaffolds with varying polyA linkers)
Concentration: 0, 10, 20, 40, 80, 160 μM
Incubation Time: 24 h
Result: Showed RNA scaffolds with 5A, 10A, 20A, and 30A linkers induced partial p50 degradation, with 10A and 20A linkers yielding better results.
Revealed the best p50 degradation at 20 μM, with a hook effect observed at higher concentrations.
Exhibited no significant p50 degradation in cells expressing only the p50 aptamer or only Broccoli.

Western Blot Analysis

Cell Line: human breast cancer MCF-7 cells (transfected with plasmids encoding B-20A-p50 RNA scaffold and NF-kB-driven GFP reporter cassette)
Concentration: 20 μM
Incubation Time: 24 h
Result: Showed GFP fluorescence (driven by NF-kB activation) was significantly reduced in cells treated with TNF-α and Dth.
Revealed upregulated IkBα and proapoptotic Bax, and downregulated antiapoptotic Bcl-2 and angiogenesis-related VEGF via western blot.

Western Blot Analysis

Cell Line: human breast cancer MCF-7 cells (transfected with plasmids encoding Broccoli-p65 or Broccoli-E2F1 RNA scaffolds with varying polyA linkers)
Concentration: 0, 10, 20, 30 μM
Incubation Time: 24 h
Result: Showed for p65, RNA scaffolds with 20A linker yielded optimal degradation, and p65 levels decreased in a dose-dependent manner with Dth treatment.
Revealed for E2F1, RNA scaffolds with 30A linker yielded optimal degradation.
Confirmed pretreatment with MG132 blocked p65 degradation, and thalidomide/DFHBI alone did not induce degradation of either protein.

Western Blot Analysis

Cell Line: human breast cancer MCF-7 cells (transfected with plasmids encoding triple-aptamer p50-Broccoli-E2F1 RNA scaffolds with varying polyA linkers)
Concentration: 0, 10, 20, 30 μM
Incubation Time: 24-48 h (24 h for western blot; 48 h for cell viability)
Result: Showed RNA scaffolds with 5A, 10A, 20A, and 30A linkers induced significant degradation of both p50 and E2F1, with the 20A linker yielding the best results.
Revealed both proteins decreased in a dose-dependent manner with Dth treatment, reaching maximum degradation after 24 h.
Showed cell viability was significantly reduced compared to controls via CCK-8 assay, with simultaneous degradation of p50 and E2F1 inhibiting proliferation more strongly than single-target degradation.

Immunofluorescence

Cell Line: HEK-293T cells
Concentration: 20 μM
Incubation Time: 1.5 h
Result: Colocalized with exogenous mCherry via the Broccoli-MS2 RNA scaffold.

化学信息

分子量 593.58
分子式 C30H29F2N5O6
别名 DFHBI-thalidomide

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础